Clinical trial NCT01935531: Effects of Topical Diclofenac on Tumor Metabolism
Official title: Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Actinic Keratoses
Keywords: actinic keratoses
tumor metabolism
glycolysis
diclofenac
warburg effect
Lead sponsor: University Hospital Regensburg
Sponsor class: OTHER
Collaborators: name: German Research Foundation
First posted: 2013-09-05
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The rationale of this study is to investigate the effects of topical diclofenac on tumor metabolism in the treatment of actinic keratoses in immunocompetent and immunocompromised patients.

Study hypothesis is that topical diclofenac lowers lactate level in skin biopsies of actinic keratoses. Planned number of patients is 38.

This study is a monocenter study investigating the effects of 3% diclofenac in 2.5% hyaluronic acid gel on tumor metabolism in the treatment of actinic keratoses. Treatment duration is 3 months. Skin biopsies will be obtained before treatment, at the end of the treatment and four weeks after the treatment. Control biopsies at visit 1 and 3 are performed in healthy, sun damaged and untreated skin. Evaluation of efficacy will be performed at the end of the treatment and four weeks after the treatment.

Duration of treatment is 3 months (±4 weeks). Approximately 0,5g Solaraze® 3% gel is applied on a 5cm x 5cm lesion. Solaraze® 3% gel is applied twice daily on the study lesions.

Detailed description: Neoplastic cells show an increased glucose metabolism and glycolysis which is associated with high lactate concentrations. There is also data for several tumor entities that high levels of lactate in the tumor are associated with tumor progression, metastasis and poor clinical outcome. Kreutz et al. demonstrated that diclofenac inhibits tumor cell proliferation in vitro and tumor growth in vivo via COX-independent effects on glucose metabolism. Diclofenac is taken up by tumor cells and inhibits tumor cell proliferation through inhibition of the oncogene MYC and subsequently glycolysis and block of lactate transport. MYC regulates genes involved in glycolysis and is upregulated in neoplastic cells, which is in line with the metabolic switch to glycolysis, the so called "Warburg effect", that cancer cells show. Although these results were found in vitro using human melanoma cells and in vivo in a mouse model, a similar mechanism of action is assumed to be relevant for the treatment of actinic keratoses with topical diclofenac. However tumor metabolism in diclofenac-treated actinic keratoses has never been investigated. To investigate the mechanism of action of diclofenac in the treatment of actinic keratoses, a clinical study analyzing particularly lactate levels, glycolysis and inflammatory infiltrate is needed.

Eligibility criteria: Inclusion Criteria:

* Written informed consent has been signed prior to or at Screening Visit
* Caucasian male and female patients
* Age \> 18 years
* Negative pregnancy test in women of childbearing age
* Clinical diagnosis of actinic keratosis (AK)
* A minimum of three AK lesions

Exclusion Criteria in immunocompromised patients :

* Concomitant UV-phototherapy
* Pregnancy or lactation
* Women in child-bearing age who do not use highly efficient contraceptive methods (\<1% failure rate per year)
* Skin diseases that might interfere with response evaluation of study treatment
* Topical pretreatment of the AK study lesions with photodynamic therapy, Solaraze® 3% gel, Aldara®, 5-FU, or polyphenon E during the 8 weeks preceding study treatment
* Radiation therapy performed in the treatment area during the 3 months preceding study therapy
* Systemic treatment with diclofenac
* Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
* Conditions that might interfere with the ability to understand the study and thus give written informed consent
* Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
* Suspected lack of compliance

Exclusion criteria in immunocompetent patients:

* Concomitant UV-phototherapy
* Pregnancy or lactation
* Women in child-bearing age who do not use highly efficient contraceptive methods (\<1% failure rate per year)
* Patients with clinically relevant suppression of the immune system (e.g. drug induced, infection)
* Skin diseases that might interfere with response evaluation of study treatment
* Topical pretreatment of the AK study lesions with photodynamic therapy, Aldara®, Solaraze® 3% gel , 5-FU, or polyphenon E during the 8 weeks preceding study treatment
* Systemic treatment with cytostatic drugs or radiation therapy performed in the treatment area during the 3 months preceding study therapy
* Systemic treatment with diclofenac
* Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
* Conditions that might interfere with the ability to understand the study and thus give written informed consent
* Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion
* Suspected lack of compliance

Primary outcomes:
measure: Lactate level in skin biopsies of actinic keratoses
timeFrame: 4 weeks after the treatment
Secondary outcomes:
measure: Lactate level in skin biopsies of healthy skin in a subpopulation
timeFrame: Before treatment and 4 weeks after the treatment
measure: Glycolysis-relevant proteins evaluated using PCR and Westernblot techniques
timeFrame: at the end of the treatment and 4 weeks after the treatment
measure: Metabolic changes (e.g. glucose, amino acids)
timeFrame: at the end of the tretment and 4 weeks after the treatment
Other outcomes:
Locations:
city: Regensburg
country: Germany
facility: University hospital Regensburg
state: Bavaria
Study officials:
References:
citation: Singer K, Dettmer K, Unger P, Schonhammer G, Renner K, Peter K, Siska PJ, Berneburg M, Herr W, Oefner PJ, Karrer S, Kreutz M, Datz E. Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis. Front Oncol. 2019 Jul 3;9:605. doi: 10.3389/fonc.2019.00605. eCollection 2019.